151 related articles for article (PubMed ID: 12133721)
41. Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases.
Li Z; Ortega-Vilain AC; Patil GS; Chu DL; Foreman JE; Eveleth DD; Powers JC
J Med Chem; 1996 Sep; 39(20):4089-98. PubMed ID: 8831774
[TBL] [Abstract][Full Text] [Related]
42. Development of calpain-specific inactivators by screening of positional scanning epoxide libraries.
Cuerrier D; Moldoveanu T; Campbell RL; Kelly J; Yoruk B; Verhelst SHL; Greenbaum D; Bogyo M; Davies PL
J Biol Chem; 2007 Mar; 282(13):9600-9611. PubMed ID: 17218315
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors.
Lee KS; Seo SH; Lee YH; Kim HD; Son MH; Chung BY; Lee JY; Jin C; Lee YS
Bioorg Med Chem Lett; 2005 Jun; 15(11):2857-60. PubMed ID: 15911268
[TBL] [Abstract][Full Text] [Related]
44. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases.
Li Z; Patil GS; Golubski ZE; Hori H; Tehrani K; Foreman JE; Eveleth DD; Bartus RT; Powers JC
J Med Chem; 1993 Oct; 36(22):3472-80. PubMed ID: 8230139
[TBL] [Abstract][Full Text] [Related]
45. Developments in the design and synthesis of calpain inhibitors.
Neffe AT; Abell AD
Curr Opin Drug Discov Devel; 2005 Nov; 8(6):684-700. PubMed ID: 16312145
[TBL] [Abstract][Full Text] [Related]
46. General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.
Huang L; Ellman JA
Bioorg Med Chem Lett; 2002 Oct; 12(20):2993-6. PubMed ID: 12270191
[TBL] [Abstract][Full Text] [Related]
47. Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors.
Zhang Y; Jung SY; Jin C; Kim ND; Gong P; Lee YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):502-7. PubMed ID: 19041242
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors.
Zhang Q; Cao R; Liu A; Lei S; Li Y; Yang J; Li S; Xiao J
Bioorg Med Chem Lett; 2017 Sep; 27(17):4061-4065. PubMed ID: 28778471
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position.
Donkor IO; Korukonda R
Bioorg Med Chem Lett; 2008 Sep; 18(17):4806-8. PubMed ID: 18694642
[TBL] [Abstract][Full Text] [Related]
50. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.
Altmann E; Green J; Tintelnot-Blomley M
Bioorg Med Chem Lett; 2003 Jun; 13(12):1997-2001. PubMed ID: 12781182
[TBL] [Abstract][Full Text] [Related]
51. Calpain inhibition: a therapeutic strategy targeting multiple disease states.
Carragher NO
Curr Pharm Des; 2006; 12(5):615-38. PubMed ID: 16472152
[TBL] [Abstract][Full Text] [Related]
52. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Webber SE; Okano K; Little TL; Reich SH; Xin Y; Fuhrman SA; Matthews DA; Love RA; Hendrickson TF; Patick AK; Meador JW; Ferre RA; Brown EL; Ford CE; Binford SL; Worland ST
J Med Chem; 1998 Jul; 41(15):2786-805. PubMed ID: 9667969
[TBL] [Abstract][Full Text] [Related]
53. Beta-lactones as a new class of cysteine proteinase inhibitors: inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine beta-lactone.
Lall MS; Karvellas C; Vederas JC
Org Lett; 1999 Sep; 1(5):803-6. PubMed ID: 10823207
[TBL] [Abstract][Full Text] [Related]
54. 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors.
Zhou NE; Guo D; Thomas G; Reddy AV; Kaleta J; Purisima E; Menard R; Micetich RG; Singh R
Bioorg Med Chem Lett; 2003 Jan; 13(1):139-41. PubMed ID: 12467634
[TBL] [Abstract][Full Text] [Related]
55. Rapid optimization of an ICE inhibitor synthesis using multiple reaction conditions in a parallel array.
Warmus JS; Ryder TR; Hodges JC; Kennedy RM; Brady KD
Bioorg Med Chem Lett; 1998 Sep; 8(17):2309-14. PubMed ID: 9873533
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
57. Discovery of selective and nonpeptidic cathepsin S inhibitors.
Irie O; Ehara T; Iwasaki A; Yokokawa F; Sakaki J; Hirao H; Kanazawa T; Teno N; Horiuchi M; Umemura I; Gunji H; Masuya K; Hitomi Y; Iwasaki G; Nonomura K; Tanabe K; Fukaya H; Kosaka T; Snell CR; Hallett A
Bioorg Med Chem Lett; 2008 Jul; 18(14):3959-62. PubMed ID: 18572405
[TBL] [Abstract][Full Text] [Related]
58. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
59. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
60. Molecular modeling in cysteine protease inhibitor design.
Lindvall MK
Curr Pharm Des; 2002; 8(18):1673-81. PubMed ID: 12132998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
